About DBV Technologies
DBV Technologies is a company based in Bagneux (France) founded in 2002 by Pierre-Henri Benhamou. DBV Technologies has raised $68.86 million across 8 funding rounds from investors including Takeda Pharmaceuticals, Apax Partners and RA Capital. The company has 109 employees. DBV Technologies operates in a competitive market with competitors including Moderna, BeiGene, Biogen, Incyte and Vir Biotechnology, among others.
- Headquarter Bagneux, France
- Employees 109
- Founders Pierre-Henri Benhamou
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website dbv-technologies.com
- Social LinkedIn X
- Legal Name Dbv Technologies Sa
- Net Profit-$153 M (USD)-23.63as on Dec 31, 2025
- EBITDA-$140.62 M (USD)-13.65as on Dec 31, 2025
- Total Equity Funding$68.86M (USD)
in 8 rounds
- Latest Funding Round$306.9M (USD), Post-IPO
Apr 2025
- InvestorsTakeda Pharmaceuticals
& 14 more
- Employee Count109
Funding Insights of DBV Technologies
DBV Technologies has successfully raised a total of $68.86M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $306.9 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $68.86M
- Total Rounds 8
- Last Round Post-IPO — $306.9M
- First Round $14.92M
(Jan 2006)
- Investors Count 15
All 8 funding rounds of DBV Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $306.9M | Post-IPO | – | – | – |
| Jun 2022 | $194M | Post-IPO | – | – | |
| May 2016 | $111.23M | Post-IPO | – | – | |
| Jan 2013 | – | Grant | – | – | |
| Mar 2012 | $19.68M | Series C | – | – | |
| Jan 2011 | $25.5M | Series C | – | Lundbeck Foundation | |
| Jan 2008 | $8.77M | Series B | – | ALK-Abello, Sofinnova Partners | – |
| Jan 2006 | $14.92M | Series A | – | Apax, Sofinnova Partners | – |
15 investors in total: 15 institutional.
Investors in DBV Technologies
DBV Technologies has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, Apax Partners and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Venture capital and private equity firm | – | vivocapital.com | Palo Alto, United States | |
- | – | fonds-fsi.fr | - | |
Life science companies are funded through venture capital investments. | – | lundbeckfonden.com | Copenhagen, Denmark | |
Private equity and private debt firm focused on multiple sector | – | eiffel-ig.com | Paris, France | |
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
Equity investments are focused on tech, services, and consumer sectors. | 1981 | apax.com | Hong Kong, China | |
Offers flexible capital and partnerships to companies in life sciences sectors. | – | braidwell.com | - | |
Hotels and resorts are operated by Fairmont in global locations. | 1907 | fairmont.com | Dubai, United Arab Emirates | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for DBV Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DBV Technologies
62 people are tracked at DBV Technologies (32 in leadership, 16 in board & advisors, 14 in team); the tracked headcount is 109.
| Name | Role | Group |
|---|---|---|
Daniel Tasse | CEO | Leadership |
Pierre-Henri Benhamou | Co-Founder & CEO | Leadership |
Michele F. Robertson | Chief Legal Officer | Leadership |
Caroline Daniere | Chief Human Resources Officer & Chief of Staff | Leadership |
Virginie Boucinha | Chief Financial Officer | Leadership |
Daniel Tassé | CEO / Directeur General | Leadership |
Jeff Germani, MBA | Senior Director, Clinical Development & Medical Affairs | Leadership |
Todd Green | Vice President Clinical Development and Medical Affairs | Leadership |
Maribeth Kowalski | Senior Director, Medical & Scientific Communications and Information | Leadership |
Andrew J. Finan | Vice President, Deputy General Counsel | Leadership |
valerie Larricq | VP Supply Chain Management | Leadership |
Laura Lesage | Director, Global HR Operations And Facilities France | Leadership |
Cécile Delansorne | Head of IS | Leadership |
Salim CHKAIMI | Directeur AQ / QA Director : Audit & QSM tools | Leadership |
Pharis Mohideen | Chief Medical Officer | Leadership |
Théo Vernin | Director, IT Quality & Medical | Leadership |
Magali Vidal-Engaurran | Director QA operations | Leadership |
Callie Gautreaux | Senior Director, Quality | Leadership |
Marie-Catherine THERENE | VP Global Quality QMS & Audits, Responsible Pharmacist | Leadership |
Kevin P. Malobisky | Chief Operations Officer | Leadership |
42 more people are available in the full profile.
Complete people profiles for DBV Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of DBV Technologies
DBV Technologies is a publicly listed company on the EURONEXT with ticker symbol DBV in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Oct 2014
- Listed onNASDAQ: DBVT
- Listed entityDBV Technologies SA
- Exchange sectorHealth technology
- ISINFR0010417345
- Share price1.68 EUR (-0.65% on the day) · 2026-10-09
- Market capitalisation527,444,019.00 EUR
- EPS (diluted, trailing year)-0.60 EUR
- Volume (last session)594,470
Financials of DBV Technologies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -130.2M EUR | -119.7M EUR |
| 2024 | – | -105.3M EUR | -105.3M EUR |
| 2023 | – | -67.3M EUR | -89.4M EUR |
| 2022 | – | -91.6M EUR | -76.2M EUR |
| 2021 | – | -83.0M EUR | -79.5M EUR |
Detailed financial statements for DBV Technologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of DBV Technologies
4 dated milestones of DBV Technologies across 23 years, from founding to its latest funding, stage changes and deals.
- Founded DBV Technologies is founded.
- Funding First funding round of $14.9M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $306.9M.
Competitors of DBV Technologies
DBV Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Biogen, Incyte and Vir Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| regeneron.com | 1988 | Tarrytown, United States | – | 13,450 | Antibodies are developed for treating cancer, eye, and inflammatory diseases. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. |
Detailed competitors of DBV Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DBV Technologies
The website of DBV Technologies (dbv-technologies.com) receives about 18.3K visits a month and ranks #1,234,936 among all websites worldwide, #1,556 in Biotechnology and Pharmaceuticals.
- Monthly visits18.3K
▼ 10.4% vs previous month
- Unique visitors7.7K
per month
- Global rank#1,234,936
among all websites
- Category rank#1,556
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit2.5
- Average visit2 min 25 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with DBV Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mdedge.com | 100% | – | #128,013 | View details |
Latest news on Dbv Technologies
Complete news archive for DBV Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to DBV Technologies
10 companies that operate in the same segment as DBV Technologies (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DBV Technologies
DBV Technologies was founded in 2002 and raised its 1st funding round 4 years after it was founded.
DBV Technologies is headquartered in Bagneux, France. It is registered at Bagneux, Hauts-de-seine, France.
Daniel Tasse is the current CEO of DBV Technologies.
DBV Technologies is a funded company, having raised a total of $68.86M across 8 funding rounds to date. The company's 1st funding round was a Series A of $14.92M, raised on Jan 2006.
DBV Technologies has 109 employees.
DBV Technologies was established in 2002 in Bagneux, France, as a clinical-stage biopharmaceutical entity. Research and development are centered on epicutaneous immunotherapy for food allergies. Diagnostic solutions like Diallertest Milk are provided for identifying cows milk protein allergy in children. Treatment options under development include Viaskin Peanut for peanut allergies, Viaskin Milk for milk-related conditions, and Viaskin Egg for hens egg allergy.
DBV Technologies's top competitors include Moderna, BeiGene and ADMA Biologics.
Yes, DBV Technologies is publicly traded on EURONEXT under the ticker symbol DBV.
DBV Technologies has 15 investors. Key investors include Takeda Pharmaceuticals, Apax Partners, RA Capital, Nestlé Health Science, and Fairmont Hotels & Resorts.